MIF and glioblastoma: Finally, exploring strategies targeting macrophage inhibitory factor (MIF), a phase 1b/2a dose-escalation study investigated ibudilast—a selective MIF inhibitor—in combination with temozolomide (TMZ) for both newly diagnosed and recurrent GBM patients [84].